Dekabank Deutsche Girozentrale Reduces $306K in Arcturus Therapeutics Holdings Inc. ($ARCT)
Key Points
- Dekabank Deutsche Girozentrale changed its Arcturus Therapeutics Holdings Inc. ($ARCT) stake by 100.0% last quarter, cutting to 0 shares.
- $ARCT last traded around $6.97.
Dekabank Deutsche Girozentrale reduced its position in Arcturus Therapeutics Holdings Inc. ($ARCT), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Arcturus Therapeutics Holdings Inc. after selling 43,889 shares during the quarter.
Arcturus Therapeutics Holdings Inc. ($ARCT) Stock
Arcturus Therapeutics Holdings Inc. Earnings
Analysts Set New Price Targets
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.